KEN W. HOLLAND, R.PH.

Flemington, N.J. 08822 C: (973) 876-6171 kenholland26@yahoo.com H: (908) 806-8807

SENIOR MARKETING AND BUSINESS DEVELOPMENT PROFESSIONAL Extensive global experience on both the client and supplier side including Biotechnology and large pharma. Experience includes launch, growth and mature products in marketing planning and sales implementation with emphasis on returning maximized growth. Effective and innovative team leader, account executive with competitive selling and life-cycle strategy expertise across multiple therapeutic areas including; Cardiovascular, Ophthalmology, CNS-Pain, Arthritis, and Migraine, with annual product sales ranging from $.5B to 2.5B. Demonstrated record of success in product launches, managed care strategic account sales, re-invigorating mature franchises and competitive sales planning on a global and national scale. PROFESSIONAL EXPERIENCE INVENTIV HEALTH (2011-Current) Vice-President, Global Strategic Accounts- Developed and provided innovative pharmaceutical solutions to commercial, clinical, consulting and procurement functions within a large pharma account. Established C-level relationships and alliances across targeted client divisions and critical therapeutic functions within clinical and commercial franchises. Led account growth of 22% (2011v. 2012-projected), with significant late stage opportunities pending. Led a Strategic Account team of 30 professionals to develop and close convergent capabilities and solutions with client (contacts=155), across 25 inVentiv Health companies. NICOX INC., Warren, N.J. (2009-2010)

Senior Director, Disease Education and Patient Care

Initiate new business alliances with Societies, Sales, and MSL operations through education programs, extensive publications planning, and public relations in preparation for launch of new class of OA drugs. Responsible for pre-launch education and training materials addressing strategic priorities, specifically; NO platform, unmet need- NSAID and CV risks. MERCK AND CO. (1982-2008) Exec. Director, Global Marketing-Merck Schering Plough JV (2007 2008) Leadership of strategic and annual planning implementation across Europe for VYTORIN and ZETIA, in conjunction with both the US and Schering Plough marketing teams. 2008 annual sales in Europe were $1.2B, representing 25 % growth vs. '07.

Responsible for all promotion and sales integration issues; key customer contact, country-level implementation led to > 25 % growth and attribute tracking metrics. Coordinated strategic activities at major EU-level scientific congresses, marketing forums and sales meetings, including competitive planning, innovative exhibits, public affairs events, and satellite symposia with top global speakers focused on message retention.

Executive Director, Global Marketing-Specialty Products Group (2005 2006) Leadership and strategic support for Ophthalmic, Migraine, and Urology franchises including; Maxalt, Cosopt, Proscar and Propecia brands. Leadership responsibilities included franchise strategies, sales team support, In-licensing, promotion, budget, LROP and congress/educational activities. Results included double digit growth during tenure.

KEN W. HOLLAND, R.PH.

Page 2 MERCK Exec. Director-Specialty (continued) Responsible for strategic planning, promotional spend level and guiding sales, direct/nonpersonal promotion. Led a team of 10 Directors and managers contributing > $700 MM in annual sales in 2006

Strategic direction provided to the MAXALT franchise resulting in renewed growth ('06 sales-> $500M) while championing efforts globally to maintain focus and resources. Managed Phase II a+b strategic planning in concert with Merck Research Labs to prepare the NDA for a "first-in class" CGRP antagonist.

Executive Director, Global Arthritis & Analgesia Franchise-VIOXX (2002 2004) Led marketing strategy and communication efforts during the maturity stage of the VIOXX franchise maintaining EMEA market share while the U.S. market declined. Implemented strategy shifts, tactical plans, with regional variations, and resource requirements. New campaign was re-launched to markets to reinvigorate focus and market share! Sales grew to $ > 2.4B in last full year despite numerous external clinical and competitive challenges. Initiated and gained senior management support for an internal motivational campaign resulting in a significant positive shift in both internal and external awareness of product. Managed aggressive counter-competitive planning 2 years in advance of new class competition, which significantly reduced market share erosion. Senior Director, MAXALT/Migraine Franchise (2000 2002) Provided franchise leadership and direction to a team of 4 managers, senior medical director and support staff to grow MAXALT from a late, 4th in class entrant to the #2 brand WW and #1 in the triptan class within the dynamic segment (new and switch patients) with sales over $ 400 M. Led all strategic and tactical decisions for franchise resulting in a broadened strategic shift from, Best Brand to Best Treatment Option. MAXALT reached #1 in attribute tracker on speed of onset, and all efficacy parameters; key to its gaining market share in a limited patient sector. Chaired the Global Marketing team and represented commercial voice on the Worldwide Business Strategy team (WBST) for Migraine leading to an aggressive patent expansion strategy. Actively planned field sales counter strategies vs. new triptan entrant resulting in minimal market share success and penetration vs. MAXALT. Senior Director, Hypertension/Heart Failure Marketing- VASOTEC, PRINIVIL (1998 1999) Provided ex-US franchise Leadership for the maturing phase of the final 3 years of patent for VASOTEC in European, Latin America and Asia Pacific markets, resulting in sales peaking from $ 2.6B in 1998 to a gradual decline to $1.6B sales in '99 via implementing a Patent Loss Strategy with Optimized resourcing. Negotiated strategic academic accounts for targeted program investment. Refined the ACEI patent and Lifecycle strategy identifying "high and low-loss" market types and providing guidance on resources beyond patent expiry. VASOTEC was the first Merck drug to benefit from the Pediatric Market Exclusivity of 6 months, providing additional net sale of approximately $600 M.

KEN W. HOLLAND, R.PH.

Page 3

National Managed Care Account Executive- U.S. Human Health (1996 1998) Represented Merck Managed Care sales efforts in 8-10 HMO, Carrier and PPO accounts in NY/NJ. Point-executive targeting key customers, representing Merck products for disease management opportunities, patient management, targeted market expansion programs (e.g. Glaucoma and Osteoporosis ).Established Field sales liaison to target accounts via sales operations. Established productive relationships with senior HMO management/administrators, Medical Directors, Pharmacy Directors, Quality Assurance and Disease Managers to seek their engagement in multiple therapeutic offerings. Objective was to gain market share while providing customer return on product clinical value, reduced costs, improved HEDIS rating, etc. Awarded the AMCP Managed Care "Most Valued -Partner Award" in 1996. Marketing Manager, U.S. Human Health- COZAAR and HYZAAR (1994 1996) Leadership role in marketing/sales plans for COZAAR and HYZAAR across multiple customer segments including Managed Care sector, Hospital segment, Opinion leaders, ensuring fast adoption and maximum market share penetration. Results were unprecedented in 1995-96, as COZAAR was recognized as the "The Most Successful Product Launched", by both Merck and many competitors. Sales operations plans and targeting, developed Best BetPhysicians list. Championed significant pre-marketing campaigns and an Innovative Publication and Textbook strategy were among initiatives resulting in fast adoption and sales >$ 1.B within 2 years postlaunch. National Sales Planning Manager -Hypertension/Heartfailure (1993 1994) Managed national field sales operations, communications to ensure regions were on strategy, BME, issue-trained. Provided field feedback and competitive recommendations into marketing. Cardiovascular Health Science Associate Field Sales Manager (1991 1993) Managed field based academic team of associates calling on top-level Medical schools in the U.S. Health Education Department and Health Science Associate (1986-1991) Field Sales, Specialty Sales- Large Account Selling, Hospitals, Union clinics (1982 1991) EDUCATION B.S. Pharmacy, University of the Sciences of Philadelphia, Philadelphia, PA (Formerly Philadelphia College of Pharmacy and Science) PROFESSIONAL DEVELOPMENT Merck Six Sigma Introductory Program (2008) Leadership Training Programs (2005-2008) Liberating Structures Training (2007 - 2008) Mentor Program Participant (1999 - 2008) Negotiating to Win ( 2004) LICENSES / AFFILIATIONS Registered Pharmacist in New Jersey (active license) Member - American Pharmaceutical Association, Staff/Parish Relations United Methodist Church Associate Member - National Police Defense Foundation